Russo Suzanne M, Ove Roger, Saif Muhammad Wasif
Mitchell Cancer Institute, University of South Alabama. Mobile, AL, USA.
JOP. 2011 Mar 9;12(2):92-5.
Pancreatic cancer remains a significant cause of morbidity and mortality. While increasing treatment options have improved outcomes for many patients, they have also complicated decision-making for treatment. Unfortunately, most patients with pancreatic cancer die from their disease. Prognostic and predictive markers could play a role to improve treatment by identifying patients who may or may not require a given therapy, and determining those most likely to benefit from a therapy. At the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held in San Francisco, January 2011, several interesting abstracts were presented that focused on prognostic and predictive markers associated with pancreatic adenocarcinomas. These abstracts discuss progress made in identifying molecular subtypes of pancreatic cancers that may provide insight into selection of patients likely to benefit from certain therapies.
胰腺癌仍然是发病率和死亡率的重要原因。虽然越来越多的治疗选择改善了许多患者的治疗结果，但它们也使治疗决策变得复杂。不幸的是，大多数胰腺癌患者死于该疾病。预后和预测标志物可以通过识别可能需要或不需要特定治疗的患者，并确定最有可能从治疗中受益的患者，来改善治疗效果。在2011年1月于旧金山举行的2011年美国临床肿瘤学会（ASCO）胃肠癌研讨会上，展示了几篇有趣的摘要，这些摘要聚焦于与胰腺腺癌相关的预后和预测标志物。这些摘要讨论了在识别胰腺癌分子亚型方面取得的进展，这可能有助于深入了解选择可能从某些治疗中受益的患者。
